Impfstoffkandidat von Novavax zeigt offenbar hohe Wirksamkeit

SHOTLIST ROCKVILLE, MARYLAND, VEREINIGTE STAATEN28. APRIL 2009QUELLE: AFP1. Foto This April 28, 2009 photo shows Novavax, a Rockville, Maryland, company that in 2005 turned its attention to flu vaccines, is testing cell-based technologies to enable it to produce a flu vaccine in as little as three months, half as long as traditional flu vaccine makers, which use an egg-based process. Shortening the process is key, because flu can mutate rapidly. As concern spread about a swine flu virus outbreak, investors saw opportunity in shares of companies that make or hope to make anti-flu drugs, with Novavax shares leap 80 percent. AFP PHOTO/Paul J. RichardsLONDON, GROSSBRITANNIEN17. NOVEMBER 2020QUELLE: AFP2. Foto An illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes with the logo of US biotech company Novavax, on November 17, 2020.GAITHERSBURG, MARYLAND, VEREINIGTE STAATEN20. MÄRZ 2020QUELLE: AFP3. Foto A computer model shows the protein structure of a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the corona virus, COVID-19. 4. Foto Dr. Nita Patel, Director of Antibody discovery and Vaccine development, lifts a vial with a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19.5. Foto Dr. Nita Patel, Director of Antibody discovery and Vaccine development, returns a box of potential coronavirus, COVID-19, vaccines to a fridge at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the corona virus, COVID-19. 6. Foto Three potential coronavirus, COVID-19, vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19.